A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults

Trial Profile

A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2007

At a glance

  • Drugs Oleoyl estrone (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors TG Therapeutics
  • Most Recent Events

    • 09 Jul 2007 Status changed from in progress to completed.
    • 09 Jul 2007 Results of Manhattan Pharmaceuticals' two Phase IIa obesity trials showed no statistically significant placebo adjusted weight loss for any of the treatment arms evaluated. The company will discontinue its obesity programs based on these results.
    • 10 May 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top